Compare
Mesa Laboratories Inc vs Sypris Solutions Inc vs Cognex Corp vs Ralliant Corp
| Latest fiscal year | Mesa Laboratories Inc MLAB | Sypris Solutions Inc SYPR | Cognex Corp CGNX | Ralliant Corp RAL |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $249.13M | $119.89M | $994.36M | $2.07B |
| Revenue growth (YoY) | +3.4% | -14.5% | +8.7% | -4.0% |
| Gross margin | 63.5% | 7.8% | 66.9% | 50.3% |
| Operating margin | 7.4% | -5.5% | 16.3% | -57.2% |
| Net margin | 2.7% | -5.3% | 11.5% | -59.1% |
| Net income | $6.71M | -$6.34M | $114.44M | -$1.22B |
| EPS (Diluted) | $1.21 | -$0.28 | $0.68 | -$10.84 |
| Operating cash flow | $42.83M | -$5.73M | $245.51M | $397.60M |
| Free cash flow | $39.58M | -$6.49M | $236.77M | $358.40M |
| Cash & equivalents | $26.93M | n/a | $262.93M | $318.80M |
| Total assets | $427.75M | $107.81M | $2.02B | $3.82B |
| Total liabilities | $241.50M | $90.02M | $524.65M | $2.19B |
| Shareholders' equity | $186.25M | $17.79M | $1.49B | $1.63B |
| Return on year-end equity | 3.6% | -35.6% | 7.7% | -74.8% |
| Shares outstanding | 5.52M | n/a | 167.00M | 112.90M |
Revenue, most recent five fiscal years
| Fiscal year | Mesa Laboratories Inc | Sypris Solutions Inc | Cognex Corp | Ralliant Corp |
|---|---|---|---|---|
| Latest | $249.13M Ended 2026-03-31 | $119.89M Ended 2025-12-31 | $994.36M Ended 2025-12-31 | $2.07B Ended 2025-12-31 |
| 1 year earlier | $240.98M Ended 2025-03-31 | $140.18M Ended 2024-12-31 | $914.51M Ended 2024-12-31 | $2.15B Ended 2024-12-31 |
| 2 years earlier | $216.19M Ended 2024-03-31 | $136.22M Ended 2023-12-31 | $837.55M Ended 2023-12-31 | $2.16B Ended 2023-12-31 |
| 3 years earlier | $219.08M Ended 2023-03-31 | $110.12M Ended 2022-12-31 | $1.01B Ended 2022-12-31 | n/a |
| 4 years earlier | $184.34M Ended 2022-03-31 | $97.43M Ended 2021-12-31 | $1.04B Ended 2021-12-31 | n/a |